Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Turning Point Brands: Aktie stürzt nach CEO-Wechsel und Prognosesenkung ab (Investing.com DE) +++ TURNING POINT BRANDS Aktie -5,74%

SINO BIOPHARMACEUTICAL Aktie

 >SINO BIO Aktienkurs 
0.647 EUR    +7.2%    (TradegateBSX)
Ask: 0.669 EUR / 7478 Stück
Bid: 0.647 EUR / 7778 Stück
Tagesumsatz: 5831 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
SINO BIO Aktie über LYNX handeln
>SINO BIO Performance
1 Woche: +0,4%
1 Monat: +18,9%
3 Monate: +15,4%
6 Monate: -10,8%
1 Jahr: -33,8%
laufendes Jahr: -11,9%
>SINO BIOPHARMACEUTICAL Aktie
Name:  SINO BIOPHARMACEUTICAL
Land:  China
Sektor:  Gesundheit
ISIN/ Wkn:  KYG8167W1380 / A0CBDJ
Symbol/ Ticker:  SMZ1 (Frankfurt)
Kürzel:  FRA:SMZ1, ETR:SMZ1, SMZ1:GR
Index:  -
Profil:  Sino Biopharmaceutical Ltd. is a diversified biopharmaceutical enterprise specializing in the research, development, manufacturing, and commercialization of a wide array of pharmaceuticals. The company's primary focus lies in four major categories: m..
>Volltext..
Marktkapitalisierung:  10806.19 Mio. EUR
Unternehmenswert:  11227.77 Mio. EUR
Umsatz:  4192.73 Mio. EUR
EBITDA:  1407.52 Mio. EUR
Nettogewinn:  307.55 Mio. EUR
Gewinn je Aktie:  0.02 EUR
Schulden:  2202.56 Mio. EUR
Liquide Mittel:  1555.16 Mio. EUR
Operativer Cashflow:  -
Bargeldquote:  1.02
Umsatzwachstum:  18.29%
Gewinnwachstum:  -28.76%
Dividende je Aktie:  0.01 EUR
Dividendenrendite:  1.82%
Dividendenschätzung:  2.22%
Div. Historie:  01.09.26 - 0.0076972€
24.06.26 - 0.0056125€
>weitere anzeigen...
Insiderhandel -
Suchwörter:  SINO BIOPHARMACEUTICAL, SINO BIOPHARMA, SINO BIOPHARM, SINO BIO
Letzte Datenerhebung:  21.09.26
>SINO BIO Kennzahlen
Aktien/ Unternehmen:
Aktien: 17814.38 Mio. St.
Frei handelbar: 51.15%
Leerverk. Aktien: -
Rückkaufquote: -
Mitarbeiter: 21435
Umsatz/Mitarb.: 0.18 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 58.1%
Bewertung:
KGV: 35.02
KGV lG: 18.25
KUV: 2.54
KBV: 2.66
PEG-Ratio: -
EV/EBITDA: 7.98
Rentabilität:
Bruttomarge: 82.44%
Gewinnmarge: 7.34%
Operative Marge: 30.16%
Managementeffizenz:
Gesamtkaprendite: 3.11%
Eigenkaprendite: 7.47%
>SINO BIO Peer Group
Gesundheit, Lebererkrankungen & -behandlung/ Hepatitis, Onkologie/ Krebs- Behandlung, Herz-Kreislauf- Behandlung/ Kardiologie
 
21.09.26 - 06:30
Midday Takeaway: HSI Closes Midday at 24,891, Up 140 pts; HSTI Closes Midday at 4,400, Down 5 pts; XIAOMI Up over 3%; TS LINES, GENSCRIPT BIO, STAR SHINE HLDG, LEGENDHOLDING Hit New Highs (AAStocks)
 
At midday close, HSI rose 140 pts or 0.6% to 24,891. HSTI dropped 5 pts or 0.1% to 4,400. HSCEI gained 58 pts or 0.7% to 8,283.Active Heavyweights:XIAOMI (01810.HK) closed at $27.42, up 3.9%BABA (09988.HK) closed at $111.2, up 1.7%TENCENT (00700.HK) closed at $426.2, up 1.7%HSI & HSCEI Constituents on Move:SINO BIOPHARM (01177.H......
03.09.26 - 10:30
Full-day Takeaway: HSI Closes at 25,213, Down 97 pts; HSTI Closes at 4,468, Down 48 pts; SINO BIOPHARM Up over 6%; ABLE DIGITAL, TS LINES, TCL ELECTRONICS Hit New Highs; Market Turnover Rises (AAStocks)
 
At close, HSI dropped 97 pts or 0.4% to 25,213. HSTI dropped 48 pts or 1.1% to 4,468. HSCEI fell 64 pts or 0.8% to 8,385. Market turnover reached $199.38 billion.Active Heavyweights:PING AN (02318.HK) closed at $56.95, up 2.7%XIAOMI (01810.HK) closed at $27.44, down 2.2%BABA (09988.HK) closed at $107.5, down 2.2%MEITUAN (03690.H......
20.08.26 - 10:30
Full-day Takeaway: HSI Closes at 25,698, Up 203 pts; HSTI Closes at 4,700, Up 18 pts; SINO BIOPHARM Up over 12%; OOIL, TINGYI, GENSCRIPT BIO, CHINAGOLDINTL, SITC Hit New Highs; Market Turnover Rises (AAStocks)
 
At close, HSI rose 203 pts or 0.8% to 25,698. HSTI rose 18 pts or 0.4% to 4,700. HSCEI gained 76 pts or 0.9% to 8,547. Market turnover reached $269.12 billion.Active Heavyweights:BABA (09988.HK) closed at $126.2, up 1.6%XIAOMI (01810.HK) closed at $27.76, up 1.2%TENCENT (00700.HK) closed at $451.4, up 0.9%HSI & HSCEI Constituent......
19.08.26 - 13:36
Sino Biopharmaceutical Limited Unveils New Global Brand, SBP Group, to Accelerate International Expansion (PR Newswire)
 
HONG KONG, Aug. 19, 2026 /PRNewswire/ -- Sino Biopharmaceutical Limited (HKEX: 01177), a leading innovation-driven pharmaceutical company in China, announced the launch of its new global brand, SBP Group, during its interim results meeting. SBP stands for Science, Breakthroughs and......
08.07.26 - 16:30
Sino Biopharma receives Chinese rights to two GSK respiratory drugs (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
08.07.26 - 08:30
Sino Biopharm signs AstraZeneca licensing deal, expands GSK tie-up; shares up (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
08.07.26 - 08:30
Sino Biopharm: Aktie legt nach Deals mit AstraZeneca und GSK kräftig zu (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
08.07.26 - 05:48
AstraZeneca, Sino Biopharm Sign Up to $1.9 Billion Respiratory Drug Licensing Deal (WSJ EN)
 
Sino Biopharmaceutical will receive $200 million upfront from AstraZeneca, and will be eligible for milestone payments....
22.05.26 - 13:06
Health Care Roundup: Market Talk (WSJ EN)
 
Find insight on ConvaTec, AstraZeneca, Sino Biopharmaceutical and more in the latest Market Talks covering Health Care....
21.05.26 - 18:36
Health Care Roundup: Market Talk (WSJ EN)
 
Find insight on AstraZeneca, Sino Biopharmaceutical, ConvaTec and more in the latest Market Talks covering the Health Care sector....
11.05.26 - 18:30
GSK Targets China′s Hepatitis B Market Through New Deal (Benzinga)
 
GSK partnered with Sino Biopharmaceutical to advance hepatitis B drug bepirovirsen in China while launching its final buyback tranche. Importance Rank:  1 read more...
11.05.26 - 09:15
GSK findet für neues Hepatitis-Medikament Vertriebspartner in China (Dow Jones)
 
Von Adria Calatayud DOW JONES--GSK kooperiert mit Sino Biopharmaceutical, um die Markteinführung für sein Hepatitis-B-Medikament Bepirovirsen in China zu beschleunigen. Eine jetzt geschlossene Vereinbarung sieht vor, dass...
22.04.26 - 02:30
Sino Biopharmaceutical Subsidiary Unveils Data on Two Self-Developed ADCs at American Association for Cancer Research (AAStocks)
 
Sino Biopharmaceutical (01177.HK) announced that its wholly owned subsidiary, LaNova Medicines, presented the latest research data on two self-developed next-generation antibody-drug conjugates (ADCs), LM-364 "Nectin-4TME ADC" and LM-338 "STn ADC", at the 2026 Annual Meeting of the American Association for Cancer Research (AACR)......
20.04.26 - 11:15
Sino Biopharmaceutical Bevacizumab Biosimilar Beimu Subai Monoclonal Antibody Combined with Anlotinib Approved for New Indication (AAStocks)
 
Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...
19.04.26 - 16:15
SINO BIOPHARM Announces Preliminary Clinical Data of Innovative Drug MK-2010/LM-299 (AAStocks)
 
SINO BIOPHARM (01177.HK) announced that its wholly owned subsidiary Livzon Mabpharm has released preliminary clinical data of its self-developed innovative drug MK-2010/LM-299, a "PD-1/VEGF bispecific antibody," at the 2026 American Association for Cancer Research (AACR) Annual Meeting. A total of 112 patients received treatment......
15.04.26 - 11:45
SINO BIOPHARMACEUTICAL 's Vetricotobat Monoclonal Antibody for Gastric Cancer Completes First Patient Enrollment in Phase III Clinical Trial (AAStocks)
 
Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...
13.04.26 - 10:30
Research: M Stanley Raises Sino Biopharmaceutical TP to HKD8.3, Rating Overweight (AAStocks)
 
Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...
26.03.26 - 10:00
Results: SINO BIOPHARM Full-Yr NP Fades 33%; Final DPS HKD5 Cents (AAStocks)
 
SINO BIOPHARM (01177.HK) announced its 2025 annual results, reporting revenue of RMB31.834 billion, up 10.3% YoY. Profit attributable to shareholders was RMB2.343 billion, down 33% YoY, with an EPS of RMB13.02 cents. A final DPS of HKD5 cents was declared, compared to HKD4 cents in the same period last year. Including the interi......
05.03.26 - 05:30
Midday Takeaway: HSI Closes Midday at 25,462, Up 212 pts; HSTI Closes Midday Flat at 4,829; SINO BIOPHARM Up over 5%; KINETIC DEV Hit New Highs (AAStocks)
 
At midday close, HSI rose 212 pts or 0.8% to 25,462. HSTI stayed still at 4,829. HSCEI gained 20 pts or 0.2% to 8,504.Active Heavyweights:MEITUAN (03690.HK) closed at $74.1, down 1.7%XIAOMI (01810.HK) closed at $32.5, up 1.6%HKEX (00388.HK) closed at $410.4, up 1.4%BABA (09988.HK) closed at $128.4, down 1.2%TENCENT (00700.HK) cl......
04.03.26 - 13:00
Sanofi bets up to $1.53B to license blood cancer drug from Sino Biopharma unit (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Wer Umstände macht, muß hungern. - Sprichwort Japan
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!